Wells Fargo & Company MN lifted its stake in Coherus Biosciences Inc (NASDAQ:CHRS) by 429.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 154,026 shares of the biotechnology company’s stock after purchasing an additional 124,910 shares during the period. Wells Fargo & Company MN owned 0.27% of Coherus Biosciences worth $2,056,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. SG Americas Securities LLC boosted its position in shares of Coherus Biosciences by 32.7% in the 2nd quarter. SG Americas Securities LLC now owns 7,244 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 1,785 shares during the last quarter. Legal & General Group Plc lifted its holdings in Coherus Biosciences by 12.6% during the second quarter. Legal & General Group Plc now owns 9,341 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 1,046 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in Coherus Biosciences during the second quarter worth about $185,000. Voya Investment Management LLC lifted its holdings in Coherus Biosciences by 32.2% during the second quarter. Voya Investment Management LLC now owns 17,607 shares of the biotechnology company’s stock worth $253,000 after acquiring an additional 4,293 shares in the last quarter. Finally, Cornerstone Capital Management Holdings LLC. lifted its holdings in Coherus Biosciences by 14.6% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 23,362 shares of the biotechnology company’s stock worth $334,000 after acquiring an additional 2,979 shares in the last quarter. Institutional investors and hedge funds own 81.00% of the company’s stock.
Several research analysts have weighed in on the company. BidaskClub upgraded Coherus Biosciences from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. Citigroup reiterated a “buy” rating and set a $23.00 target price on shares of Coherus Biosciences in a report on Tuesday, November 7th. ValuEngine lowered Coherus Biosciences from a “sell” rating to a “strong sell” rating in a report on Thursday, October 26th. Zacks Investment Research lowered Coherus Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Finally, Credit Suisse Group reiterated an “outperform” rating and set a $17.00 target price (down from $24.00) on shares of Coherus Biosciences in a report on Wednesday, September 27th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $29.67.
Shares of Coherus Biosciences Inc (CHRS) opened at $12.60 on Wednesday. Coherus Biosciences Inc has a 12 month low of $8.05 and a 12 month high of $28.60. The stock has a market capitalization of $788.06, a PE ratio of -2.32 and a beta of 3.89. The company has a quick ratio of 5.46, a current ratio of 5.46 and a debt-to-equity ratio of 1.84.
Coherus Biosciences (NASDAQ:CHRS) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.83) by ($0.26). Coherus Biosciences had a negative net margin of 73.89% and a negative return on equity of 582.31%. equities research analysts forecast that Coherus Biosciences Inc will post -4.39 earnings per share for the current fiscal year.
WARNING: “Wells Fargo & Company MN Buys 124,910 Shares of Coherus Biosciences Inc (CHRS)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/17/wells-fargo-company-mn-buys-124910-shares-of-coherus-biosciences-inc-chrs.html.
Coherus Biosciences Profile
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.
Want to see what other hedge funds are holding CHRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Coherus Biosciences Inc (NASDAQ:CHRS).
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.